logo

FX.co ★ US approves resumption of Johnson & Johnson Covid-19 vaccine

US approves resumption of Johnson & Johnson Covid-19 vaccine

US approves resumption of Johnson & Johnson Covid-19 vaccine

On Wednesday, April 28, US health regulators approved the resumption of the Johnson & Johnson coronavirus vaccine after a cautionary pause to assess possible risks. The 10-day pause was taken after several cases of blood clots in women under 50 had been reported. In the week of April 26-30, the Centers for Disease Control and Prevention (CDC) allowed the use of Johnson & Johnson Covid-19 vaccine that had been previously suspended due to several cases of thrombosis and deaths within days of receiving the shot. According to Peter Marks, the head of the Food and Drug Administration's Center for Biologics Evaluation and Research, administration of the J&J vaccine will be resumed shortly. This time, the vaccine will come with a warning label about the potential risk of blood clots in women under the age of 50. Experts cannot name the exact reason for thrombosis. Among possible causes of this medical condition can be a rare immune reaction that could activate platelets to form clots, Peter Marks says. The US regulator has lifted temporary restrictions on the J&J vaccine after consulting medical specialists. Experts at the CDC's Advisory Committee on Immunization Practices have concluded that the benefits of the vaccine outweigh potential risks. On April 13, the US authorities put the vaccination rollout on halt after six women fell seriously ill with blood clots right after getting the shot. On April 24, nine more similar cases were reported in women under the age of 50. Three women died and seven remain in hospital. So far, 8 million people in the US have received the Johnson & Johnson vaccine. The J&J vaccine, just like Sputnik V developed in Russia, is based on adenoviruses. According to specialists at the Gamaleya National Research Center for Epidemiology and Microbiology, all Covid-19 drugs based on the adenovirus vector differ greatly in terms of structure and production technologies. Thus, the Russian vaccine Sputnik V is produced with the HEK293 cell line which has successfully passed clinical trials, experts at the Gamaleya Research Center emphasize.

*The market analysis posted here is meant to increase your awareness, but not to give instructions to make a trade
Go to the articles list Open trading account